| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Retrospective Evaluation of the GDF/Suez Merger: Effects on Gas Hub Prices |
0 |
0 |
0 |
46 |
1 |
1 |
5 |
83 |
| A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
0 |
23 |
0 |
1 |
3 |
43 |
| A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
1 |
21 |
0 |
0 |
1 |
36 |
| A Retrospective Study of State Aid Control in the German Broadband Market |
0 |
0 |
0 |
22 |
0 |
2 |
8 |
43 |
| A retrospective evaluation of the GDF/Suez merger: Effects on gas hub prices |
0 |
0 |
0 |
55 |
0 |
2 |
3 |
65 |
| Acquiring R&D Projects: Who, When, and What? Evidence from Antidiabetic Drug Development |
0 |
0 |
1 |
11 |
0 |
3 |
9 |
20 |
| Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development |
0 |
0 |
1 |
1 |
0 |
0 |
6 |
7 |
| Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development |
0 |
0 |
3 |
16 |
1 |
1 |
6 |
17 |
| Are M&As Spurring or Stifling Innovation? Evidence from Antidiabetic Drug Development |
0 |
2 |
26 |
26 |
1 |
9 |
37 |
37 |
| Are M&As spurring or stifling innovation? Evidence from antidiabetic drug development |
0 |
2 |
12 |
12 |
1 |
3 |
6 |
6 |
| Collusion through Joint R&D: An Empirical Assessment |
0 |
1 |
2 |
64 |
0 |
2 |
4 |
116 |
| Collusion through Joint R&D: An Empirical Assessment |
0 |
0 |
0 |
78 |
1 |
1 |
3 |
187 |
| Collusion through joint R&D: An empirical assessment |
0 |
0 |
0 |
167 |
2 |
2 |
3 |
219 |
| Common Ownership Patterns in the European Banking Sector – The Impact of the Financial Crisis |
0 |
0 |
1 |
8 |
0 |
0 |
2 |
11 |
| Common Ownership and Market Entry: Evidence from Pharmaceutical Industry |
0 |
0 |
0 |
61 |
0 |
2 |
7 |
257 |
| Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry |
0 |
0 |
0 |
60 |
3 |
4 |
13 |
232 |
| Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry |
0 |
1 |
2 |
55 |
1 |
3 |
8 |
90 |
| Common Ownership in the US Pharmaceutical Industry: A Network Analysis |
0 |
0 |
1 |
15 |
1 |
3 |
4 |
42 |
| Common Ownership in the US Pharmaceutical Industry: A Network Analysis |
0 |
0 |
1 |
22 |
1 |
1 |
3 |
65 |
| Common Ownership: Europe vs. the US |
0 |
0 |
1 |
6 |
2 |
3 |
5 |
12 |
| Common ownership and market entry: Evidence from the pharmaceutical industry |
0 |
0 |
0 |
17 |
0 |
3 |
6 |
89 |
| Common ownership and market entry: Evidence from the pharmaceutical industry |
0 |
0 |
0 |
98 |
1 |
2 |
7 |
115 |
| Common ownership in the US pharmaceutical industry: A network analysis |
0 |
0 |
0 |
13 |
0 |
3 |
4 |
34 |
| Common ownership in the US pharmaceutical industry: A network analysis |
0 |
0 |
0 |
15 |
3 |
4 |
4 |
24 |
| Common ownership: Europe vs. the US |
0 |
0 |
0 |
5 |
0 |
0 |
5 |
19 |
| Effective European Antitrust: Does EC Merger Policy Generate Deterrence |
0 |
0 |
0 |
44 |
1 |
1 |
2 |
68 |
| Effective European Antitrust: Does EC Merger Policy Generate Deterrence |
0 |
0 |
0 |
34 |
0 |
1 |
1 |
63 |
| Effective European antitrust: Does EC merger policy generate deterrence? |
0 |
0 |
0 |
1 |
1 |
1 |
4 |
40 |
| How to Measure the Deterrence Effects of Merger Policy: Frequency or Composition? |
0 |
0 |
0 |
45 |
3 |
7 |
9 |
223 |
| How to Measure the Deterrence Effects of Merger Policy: Frequency or Composition? |
0 |
0 |
0 |
57 |
1 |
1 |
1 |
164 |
| Interactions Between Product and Labour Market Reforms |
0 |
0 |
0 |
283 |
1 |
4 |
7 |
1,084 |
| Merger Clusters during Economic Booms |
0 |
0 |
1 |
100 |
1 |
1 |
5 |
392 |
| Merger Failures |
0 |
0 |
1 |
450 |
2 |
5 |
7 |
1,331 |
| Merger failures |
0 |
0 |
1 |
229 |
1 |
2 |
8 |
579 |
| Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
1 |
6 |
1 |
1 |
4 |
74 |
| Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
192 |
0 |
2 |
2 |
472 |
| Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
86 |
2 |
3 |
3 |
446 |
| Mergers, Investment Decisions and Internal Organisation |
0 |
0 |
0 |
343 |
2 |
2 |
3 |
1,288 |
| On The Stability of Research Joint Ventures: Implications for Collusion |
0 |
0 |
0 |
68 |
1 |
1 |
1 |
224 |
| On the Stability of Research Joint Ventures: Implications for Collusion |
0 |
0 |
0 |
71 |
3 |
4 |
4 |
267 |
| Ownership Diversification and Product Market Pricing Incentives |
0 |
0 |
0 |
1 |
0 |
0 |
3 |
6 |
| Ownership Diversification and Product Market Pricing Incentives |
0 |
0 |
0 |
17 |
4 |
12 |
15 |
54 |
| Ownership diversification and product market pricing Incentives |
0 |
0 |
0 |
2 |
3 |
5 |
12 |
18 |
| R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
9 |
1 |
2 |
3 |
23 |
| R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
3 |
3 |
3 |
6 |
29 |
| R&D Spillovers through RJV Cooperation |
0 |
0 |
0 |
5 |
2 |
3 |
5 |
17 |
| R&D Spillovers throught RJV Cooperation |
0 |
0 |
0 |
18 |
2 |
5 |
6 |
52 |
| Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
0 |
48 |
1 |
1 |
2 |
195 |
| Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
0 |
51 |
0 |
1 |
2 |
201 |
| Remedy for Now but Prohibit for Tomorrow: The Deterrence Effects of Merger Policy Tools |
0 |
0 |
0 |
69 |
1 |
2 |
2 |
278 |
| Screening and Merger Activity |
0 |
0 |
0 |
91 |
1 |
1 |
5 |
359 |
| The Contingent Effect of Alliance Design on Alliance Dynamics and Performance: An Experimental Study |
0 |
0 |
0 |
30 |
1 |
2 |
5 |
55 |
| The Deterrence Effects of U.S. Merger Policy Instruments |
0 |
0 |
0 |
32 |
0 |
1 |
1 |
141 |
| The Deterrence Effects of U.S. Merger Policy Instruments |
0 |
0 |
0 |
15 |
2 |
2 |
6 |
97 |
| The Dynamics of Research Joint Ventures: A Panel Data Analysis |
0 |
0 |
0 |
96 |
1 |
2 |
3 |
314 |
| The Dynamics of Research Joint Ventures: A Panel Data Analysis |
0 |
0 |
0 |
108 |
0 |
1 |
1 |
375 |
| The Impact of Competition Policy Enforcement on the Functioning of EU Energy Markets |
0 |
1 |
1 |
136 |
2 |
4 |
6 |
134 |
| US and EU Secure Vaccine Production on Home Soil |
0 |
0 |
0 |
13 |
0 |
0 |
2 |
52 |
| USA und EU setzen auf lokale Impfstoffproduktion - Versorgungssicherheit im Fokus |
0 |
0 |
0 |
3 |
1 |
1 |
2 |
26 |
| What Clients Want: Choices between Lawyers' Offerings |
0 |
0 |
0 |
13 |
1 |
3 |
6 |
56 |
| What Clients want: Choices between Lawyers' Offerings |
0 |
0 |
0 |
17 |
0 |
1 |
1 |
49 |
| What clients want: Choices between lawyers' offerings |
0 |
0 |
0 |
2 |
1 |
2 |
5 |
32 |
| Total Working Papers |
0 |
7 |
57 |
3,705 |
66 |
145 |
322 |
11,147 |
LogEc is hosted by the
Örebro University School of Business.